Reference number : GC-2017-Q1-00242, amendment number : , agreement type : G, recipient legal name : Barthelat, Francois (McGill University)|Barthelat, Francois (Université McGill), recipient country : CA, recipient province : nan, recipient city : Quebec|Québec, recipient postal code : nan, program name english : Collaborative Health Research Projects, program name french : Projets de recherche concertée sur la santé, program purpose english : Due to the ageing world population, techniques to replace, restore, or regenerate bone have_x000D_
become a major clinical need in the fields of orthopaedic, spinal, dental, cranial, and_x000D_
maxillofacial surgery. For these patients that suffer from bone loss and bone defects, surgical_x000D_
treatment remains a major challenge. Traditional bone grafting techniques have performance_x000D_
limitations including donor site morbidity, viral transmission, immunologic incompatibility, long_x000D_
rehabilitation time and structural failure. The need for new strategies for the treatment of bone_x000D_
defects is therefore urgent. The ideal bone graft material must: (i) match the mechanical_x000D_
properties of healthy bone; (ii) be biocompatible and promote healing and (iii) must degrade_x000D_
over time to be replaced by healthy bone. To this day, there is no synthetic material that can_x000D_
fulfill these three requirements simultaneously. In this project we will develop a new structural_x000D_
bone graft made from calcium sulfate, collagen and gelatin. All components of this material_x000D_
are fully biocompatible and FDA-approved for use as biomaterials. The mineral content_x000D_
provides stiffness, while the weaker protein layers can deflect incoming cracks to generate_x000D_
toughness. The implication is that this material can be used to fabricate load-carrying grafts,_x000D_
as opposed to traditional calcium phosphates/sulfates which are too brittle. The structural_x000D_
bone graft can be of varying sizes and dimensions. In-vivo performance will be evaluated with_x000D_
an animal study. In addition, bone grafts with complex patient-specific shapes will be_x000D_
developed using 3D printed polymeric templates. This new medical technology will have a_x000D_
significant impact on restoring functionality and quality of life in patients requiring_x000D_
reconstruction of structural bone defects secondary to trauma, failed arthroplasties, bone_x000D_
tumors, maxillofacial surgery or other bone diseases., program purpose french : Due to the ageing world population, techniques to replace, restore, or regenerate bone have_x000D_
become a major clinical need in the fields of orthopaedic, spinal, dental, cranial, and_x000D_
maxillofacial surgery. For these patients that suffer from bone loss and bone defects, surgical_x000D_
treatment remains a major challenge. Traditional bone grafting techniques have performance_x000D_
limitations including donor site morbidity, viral transmission, immunologic incompatibility, long_x000D_
rehabilitation time and structural failure. The need for new strategies for the treatment of bone_x000D_
defects is therefore urgent. The ideal bone graft material must: (i) match the mechanical_x000D_
properties of healthy bone; (ii) be biocompatible and promote healing and (iii) must degrade_x000D_
over time to be replaced by healthy bone. To this day, there is no synthetic material that can_x000D_
fulfill these three requirements simultaneously. In this project we will develop a new structural_x000D_
bone graft made from calcium sulfate, collagen and gelatin. All components of this material_x000D_
are fully biocompatible and FDA-approved for use as biomaterials. The mineral content_x000D_
provides stiffness, while the weaker protein layers can deflect incoming cracks to generate_x000D_
toughness. The implication is that this material can be used to fabricate load-carrying grafts,_x000D_
as opposed to traditional calcium phosphates/sulfates which are too brittle. The structural_x000D_
bone graft can be of varying sizes and dimensions. In-vivo performance will be evaluated with_x000D_
an animal study. In addition, bone grafts with complex patient-specific shapes will be_x000D_
developed using 3D printed polymeric templates. This new medical technology will have a_x000D_
significant impact on restoring functionality and quality of life in patients requiring_x000D_
reconstruction of structural bone defects secondary to trauma, failed arthroplasties, bone_x000D_
tumors, maxillofacial surgery or other bone diseases., agreement title english : Novel multilayered synthetic structural bone graft materials which combine biocompatibility, biodegradability and high toughness, agreement title french : Novel multilayered synthetic structural bone graft materials which combine biocompatibility, biodegradability and high toughness, agreement number : CHRPJ, agreement value : 163223.0, agreement start date : 2017-04-25, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2020-2021), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2020-2021), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada